MHRA — authorised 15 September 2022
- Marketing authorisation holder: ELI LILLY NEDERLAND B.V.
- Status: approved
🇬🇧 Mounjaro in United Kingdom
MHRA authorised Mounjaro on 15 September 2022 · NICE has issued 2 UK HTA decisions
Marketing authorisation
Health technology assessment
2 decisions from NICE for Mounjaro in United Kingdom.
NICE TA1026 — ✓ Recommended
- Indication assessed: managing overweight and obesity
NICE recommended Mounjaro for managing overweight and obesity. The decision was made without a reported ICER, and there is a commercial arrangement in place. No restrictions or conditions were applied to the recommendation.
NICE TA924 — ✓ Recommended
- Indication assessed: treating type 2 diabetes
NICE recommended Mounjaro for treating type 2 diabetes. The decision was made without a reported ICER. A commercial arrangement was in place. There were no restrictions or conditions placed on the use of Mounjaro.
Mounjaro in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United Kingdom
Frequently asked questions
Is Mounjaro approved in United Kingdom?
Yes. MHRA authorised it on 15 September 2022.
Who is the marketing authorisation holder for Mounjaro in United Kingdom?
ELI LILLY NEDERLAND B.V. holds the UK marketing authorisation.
Has Mounjaro been assessed by UK health technology agencies?
Yes — 2 UK HTA decisions on record from NICE.